Table 1.
Patient characteristics.
| Total | |
|---|---|
| (N = 62), n (%) | |
| Age | |
| Mean [years] | 63 |
| Range [years] | 34–90 |
| Elderly (>70) | 17 (27.4) |
| Sex | |
| Male | 44 (71.0) |
| Female | 18 (29.0) |
| ECOG | |
| 0–1 | 37 (59.7) |
| ≥2 | 21 (33.9) |
| Tumor type | |
| Lung | 20 (32.3) |
| Head neck | 12 (19.4) |
| Skin | 8 (12.9) |
| Urinary tract | 6 (9.7) |
| Breast | 3 (4.8) |
| Others | 13 (21.0) |
| One-drug immunotherapy | |
| Pembrolizumab/nivolumab | 41 (66.1) |
| Atezolizumab | 9 (14.5) |
| Ipilimumab | 1 (1.7) |
| Two-drug immunotherapy | |
| Nivolumab + ipilimumab | 11 (17.7) |
| Additional therapy | |
| Additional chemotherapy | 16 (25.8) |
| Additional radiotherapy | 13 (21.0) |
| Line of therapy | |
| 1 | 15 (24.2) |
| 2 | 16 (25.8) |
| 3 | 14 (22.6) |
| 4 | 7 (11.3) |
| ≥5 | 10 (16.1) |
| Mean | 2.8 |
| Number of organs with metastasis | |
| Mean | 1.8 |